The Fusion Protocol combines as-needed treatment with a maintenance regimen, so that even when wet age-related macular degeneration (AMD) appears inactive, treatment continues to prevent recurrences. In this way, the treatment takes the initiative, not the disease. Unfortunately, waiting for the disease to be controlled with just a few injections and then stopping treatment is more an illusion than reality, as this occurs in a very small percentage of patients. Relying on this possibility risks undertreating the majority of patients, leading to irreversible vision loss and much less favorable medium- and long-term outcomes.
The Institut de la Màcula developed this protocol after extensive research and studies, implementing individualized guidelines for each patient.
Currently, the Fusion Protocol has been successfully applied for years at our center, achieving visual improvement and, importantly, maintaining this improvement over the long term—unlike other strategies.